Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

MEK Inhibition Induces Differentiation in RAS-Driven Rhabdomyosarcoma

DOI: 10.1158/2159-8290.CD-RW2018-118 Published September 2018
  • Article
  • Info & Metrics
Loading
  • Major finding: In fusion-negative rhabdomyosarcoma (FN-RMS), MEK inhibition relieves ERK2-mediated repression of MYOG.

  • Mechanism: MEK inhibition induces MYOG-mediated chromatin remodeling to promote differentiation and slow tumorigenesis.

  • Impact: MEK inhibitors may induce tumor differentiation and synergize with IGF1R inhibition in patients with FN-RMS.

Fusion-negative rhabdomyosarcomas (FN-RMS), which lack PAX3/7 gene rearrangements, arise from skeletal muscle precursor cells that fail to differentiate despite expression of the myogenic master transcription factor MYOD1. These tumors commonly harbor mutations in RAS isoforms (NRAS, HRAS, or KRAS), but the role of RAS in FN-RMS differentiation blockade and tumorigenesis has not been well described. Yohe, Gryder, and colleagues performed a high-throughput drug screen to discover compounds that selectively target FN-RMS cells. Oncogenic RAS was required for FN-RMS survival and activated the MAPK pathway to block myoblast differentiation and, consistent with these findings, the MEK inhibitor trametinib selectively reduced FN-RMS cell viability, upregulated the prodifferentiation myogenic transcription factor MYOG, and induced myogenic differentiation. Mechanistically, ERK2 bound to myogenic differentiation genes, including the promoter of MYOG, where it phosphorylated RNA Pol II, resulting in RNA Pol II stalling and transcriptional repression. MEK inhibition resulted in release of ERK2 from the MYOG promoter, facilitating MYOG transcription. Trametinib treatment also resulted in MYOG-dependent chromatin remodeling, resulting in open chromatin and establishment of superenhancers at genes required for late myogenic differentiation (including MYH3). In vivo, MEK inhibition induced differentiation to suppress the growth of RAS-mutant RMS xenografts. To find possible drug combinations that might improve therapeutic efficacy, a combinatorial drug screen was performed. The IGF1R inhibitor BMS-754807 synergized with trametinib to induce tumor regression in mice with RAS-driven RMS. In addition to uncovering a mechanism by which RAS signaling suppresses MYOG expression to block MYOG-dependent chromatin remodeling and cellular differentiation in FN-RMS, these findings suggest that patients with FN-RMS may benefit from combination therapy with MEK and IGF1R inhibitors.

Yohe ME, Gryder BE, Shern JF, Song YK, Chou HC, Sindiri S, et al. MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma. Sci Transl Med 2018;10:eaan4470.

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2018 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 8 (9)
September 2018
Volume 8, Issue 9
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
MEK Inhibition Induces Differentiation in RAS-Driven Rhabdomyosarcoma
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
MEK Inhibition Induces Differentiation in RAS-Driven Rhabdomyosarcoma
Cancer Discov September 1 2018 (8) (9) OF13; DOI: 10.1158/2159-8290.CD-RW2018-118

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
MEK Inhibition Induces Differentiation in RAS-Driven Rhabdomyosarcoma
Cancer Discov September 1 2018 (8) (9) OF13; DOI: 10.1158/2159-8290.CD-RW2018-118
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • In Vivo CRISPR Screen Identifies FLI1 as Regulator of Effector T Cells
  • Trial Supports Combination Treatment and New Target for Multiple Myeloma
  • Mitochondrial DNA Damage Triggers an IFN-Mediated Immune Response
Show more Research Watch

Epigenetics

  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
  • FBXO44 Silences Repetitive Elements during DNA Replication in Cancer
  • H1 Loss Increases Accessibility of Stemness Genes to Drive Lymphoma
Show more Epigenetics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement